Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis.

@article{Min2014AntiPD1FI,
  title={Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis.},
  author={Le Min and Frank Stephen Hodi},
  journal={Cancer immunology research},
  year={2014},
  volume={2 1},
  pages={
          15-8
        }
}
Treatment with fully human monoclonal antibodies against programmed death 1 (PD1) receptor has shown great promise for a number of advanced malignancies. Although inflammatory adverse events have been well described with anti-CTL antigen 4 (CTLA4) therapy, experience with the range of adverse effects of anti-PD1 remains comparatively limited. Here, we report on a patient with advanced mucosal melanoma who received four doses of MK-3475, a fully human monoclonal antibody against PD1, and… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 43 CITATIONS, ESTIMATED 50% COVERAGE

86 Citations

0102030'14'15'16'17'18'19
Citations per Year
Semantic Scholar estimates that this publication has 86 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 13 REFERENCES

Similar Papers

Loading similar papers…